TRAIL Monoclonal antibody

TRAIL Monoclonal Antibody for WB, IHC, ELISA

Host / Isotype

Mouse / IgG1


Human and More (1)







Cat no : 66756-1-Ig


Apo 2 ligand, Apo 2L, APO2L, CD253, Protein TRAIL, TL2, TNFSF10, TRAIL

Tested Applications

Positive WB detected inhuman milk tissue
Positive IHC detected inhuman tonsillitis tissue, human prostate cancer tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0

Recommended dilution

Western Blot (WB)WB : 1:500-1:2000
Immunohistochemistry (IHC)IHC : 1:50-1:500
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

Product Information

66756-1-Ig targets TRAIL in WB, IF, IHC, ELISA applications and shows reactivity with Human samples.

Tested Reactivity Human
Cited Reactivityhuman
Host / Isotype Mouse / IgG1
Class Monoclonal
Type Antibody
Immunogen TRAIL fusion protein Ag25746
Full Name tumor necrosis factor (ligand) superfamily, member 10
Calculated Molecular Weight 281 aa, 33 kDa
Observed Molecular Weight 28-30 kDa
GenBank Accession NumberBC032722
Gene Symbol TNFSF10
Gene ID (NCBI) 8743
Conjugate Unconjugated
Form Liquid
Purification MethodProtein A purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.

Background Information

TNFSF10/TRAIL (tumor necrosis factor superfamily member 10) is a typical death ligand expressed on natural killer cells and cytotoxic T lymphocytes. This protein preferentially induces apoptosis in transformed and tumor cells, but does not appear to kill normal cells although it is expressed at a significant level in most normal tissues. TNFSF10 induces apoptotic cell death in cancer by binding to its functional death receptors, death receptor (DR) 4 (TNFRSF10A/TRAIL-R1) and DR5 (TNFRSF10B/TRAIL-R2) to activate the extrinsic apoptosis pathway. TRAIL also activates c-Jun N-terminal kinase (MAPK8/JNK) and the transcription factor nuclear factor-κB (NFκB). The binding of this protein to its receptors has been shown to trigger the activation of MAPK8/JNK, caspase 8, and caspase 3.


Product Specific Protocols
WB protocol for TRAIL antibody 66756-1-IgDownload protocol
IHC protocol for TRAIL antibody 66756-1-IgDownload protocol
Standard Protocols
Click here to view our Standard Protocols



Adv Healthc Mater

TRAIL-Armed ER Nanosomes Induce Drastically Enhanced Apoptosis in Resistant Tumor in Combination with the Antagonist of IAPs (AZD5582).

Authors - Huan Hou

Cancers (Basel)

Extracellular Vesicle Delivery of TRAIL Eradicates Resistant Tumor Growth in Combination with CDK Inhibition by Dinaciclib.

Authors - Changhong Ke

Front Bioeng Biotechnol

The inhibitory effect of human umbilical cord mesenchymal stem cells expressing anti-HAAH scFv-sTRAIL fusion protein on glioma

Authors - Tian Xue